View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+
Protocol-ID: 970 V1.2 (Mini), STUDY LEVEL - NIVO240/GEMC1000/OXAL100, DLBCL, C2+Study protocol, available to authorized participants only.
Indication(s)
- NHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive; ICD-10 C84.6
- NHL, B-Cell Type, Diffuse Large Cell; ICD-10 C83.3
- NHL, B-Cell Type, Follicular grade IIIb; ICD-10 C82.-, C82.7, C82.9
- NHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell Lymphoma; ICD-10 C85.2
- NHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negative; ICD-10 C84.7
- NHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positive; ICD-10 C84.6
- NHL, T-Cell Type, Angioimmunoblastic; ICD-10 C86.5
- NHL, T-Cell Type, Enteropathy Type; ICD-10 C86.2
- NHL, T-Cell Type, Hepatosplenic; ICD-10 C86.1
- NHL, T-Cell Type, Peripheral, Unspecified; ICD-10 C84.4
- NHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell Leukemia; ICD-10 C94.7-
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 30.05.2024